Brief: Cingulate Receives Complete Response Letter From FDA For CTx-1301
02/06/2026 13:07
BRIEF-Cingulate Receives Complete Response Letter From FDA For CTx-1301 June 2 (Reuters) - Cingulate Inc CING.O:
CINGULATE RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR CTX-1301
CINGULATE - FDA IDENTIFIES CMC REQUESTS, NO CURRENT SAFETY OR EFFICACY CONCERNS FOR CTX-1301
CINGULATE - EXPECTS PROMPT SUBMISSION OF REQUESTED INFORMATION TO FDA
CINGULATE - HAS NEARLY $30 MILLION IN CASH RESERVES TO FUND OPERATIONS INTO 2027
Source text: ID:nGNX4d3dbC
Further company coverage: CING.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cingulate
See all newsBrief: Cingulate Announces Publication Of Phase 3 Adhd Trial Results In Journal Of Child And Adolescent Psychopharmacology
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)